Loading...
Adjuvant chemotherapy has been shown to confer a modest incremental survival benefit for patients with stage III colon cancer (N Engl J Med 2004; 350:2343). Recent studies support reducing the duration of adjuvant therapy from a standard 6 months to 3 months for lower-risk patients (NEJM JW Oncol Hematol May 2018 and N Engl J Med 2018; 378:1177). Prognostic biomarkers to identify lower-risk patients have been limited to tumor location, T stage, and N stage at surgery.
To determine the prognostic value of circulating tumor DNA (ctDNA) in this setting, investigators in Australia conducted a multicenter, population-based, cohort study of 96 patients with newly diagnosed stage III colon cancer who had at least 1 of 15 tumor-specific DNA mutation…